Table 3. Subgroup analysis by prognostic factors in multivariate analysis in the propensity-matched cohort *.
| Overall survival | Distant metastasis-free survival | Locoregional relapse-free survival | ||||
|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Age | ||||||
| <45 ys | 0.38 (0.08–1.89) | 0.237 | 0.45 (0.09–2.19) | 0.324 | 0.93 (0.34–2.57) | 0.885 |
| ≥45 ys | 0.87 (0.37–2.06) | 0.752 | 0.87 (0.31–2.41) | 0.789 | 0.73 (0.27–1.99) | 0.539 |
| Sex | ||||||
| Male | 0.56 (0.23–1.38) | 0.209 | 0.78 (0.31–1.93) | 0.589 | 0.74 (0.30–1.87) | 0.526 |
| Female | 1.69 (0.35–8.04) | 0.511 | 0.14 (0.01–1.31) | 0.085 | 1.10 (0.33–3.65) | 0.873 |
| Histology | ||||||
| II | - | - | - | - | - | - |
| III | 0.77 (0.37–1.59) | 0.473 | 0.69 (0.30–1.58) | 0.383 | 0.82 (0.40–1.67) | 0.586 |
| Stage | ||||||
| T1N1 | 0.58 (0.10–3.17) | 0.527 | 0.35 (0.07–1.80) | 0.209 | 0.94 (0.22–3.95) | 0.930 |
| T2N0 | 0.22 (0.02–3.11) | 0.263 | - | 0.927 | 1.11 (0.07–18.44) | 0.942 |
| T2N1 | 1.01 (0.23–4.39) | 0.993 | 0.47 (0.11–2.09) | 0.325 | 1.12 (0.40–3.17) | 0.827 |
| T3N0 | 0.70 (0.11–4.57) | 0.713 | 2.61 (0.20–33.48) | 0.461 | 0.41 (0.07–2.50) | 0.331 |
Abbreviations: CI = confidence interval
*
Adjusted for age (continuous), sex, histology, VCA-IgA (<80/80–320/≥ 320), EA-IgA (<10/10–40/≥ 40), T-stage and N-stage with a robust variance estimator to account for the clustering within matched pair.